Topical Drug Treatment of Rosacea in Switzerland: A Descriptive Study Using Swiss Claims Data.

ABSTRACT:

Introduction

Rosacea, a chronic inflammatory condition primarily affecting the skin of the face, has long been an area of interest for pharmaceutical advancements. In Switzerland, metronidazole was the only first-line topical rosacea medication (TRM), until brimonidine was licensed in 2014 and ivermectin in 2016. We aimed to evaluate the use of TRM between 2012 and 2023 in Switzerland.

Methods

We used healthcare claims data from the Swiss health insurance "Helsana Group" between 2012 and 2023 (study period). We quantified the monthly number of claims for each TRM per 10,000 insured persons, as well as the overall and annual prevalence of patients treated with TRM in Switzerland, stratified by age (≥/<50 years) and sex in 2023. Among all continuously enrolled persons (period

SUBMITTER: Zappala T 

PROVIDER: S-EPMC12500275 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature